MCID: BPL002
MIFTS: 48

Bipolar I Disorder

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Bipolar I Disorder

MalaCards integrated aliases for Bipolar I Disorder:

Name: Bipolar I Disorder 12 75 15 17 72

Classifications:



External Ids:

Disease Ontology 12 DOID:14042
ICD9CM 35 296.50
SNOMED-CT 68 49468007
UMLS 72 C0236773 C0853193

Summaries for Bipolar I Disorder

Disease Ontology : 12 A bipolar disorder that is characterized by at least one manic or mixed episode.

MalaCards based summary : Bipolar I Disorder is related to substance abuse and social phobia. An important gene associated with Bipolar I Disorder is BDNF (Brain Derived Neurotrophic Factor), and among its related pathways/superpathways are G-Beta Gamma Signaling and Neuroscience. The drugs Oxcarbazepine and Coal tar have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 75 Bipolar I disorder (BD-I; pronounced "type one bipolar disorder") is a type of bipolar spectrum disorder... more...

Related Diseases for Bipolar I Disorder

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar I Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Related Disease Score Top Affiliating Genes
1 substance abuse 30.9 SLC6A4 DRD2 COMT BDNF
2 social phobia 30.5 SLC6A4 HTR1A DRD2
3 conduct disorder 30.5 SLC6A4 DRD2 COMT
4 dysthymic disorder 30.4 SLC6A4 HTR2A
5 drug dependence 30.4 SLC6A4 DRD2 BDNF
6 schizophreniform disorder 30.4 NRG1 DRD2 COMT
7 substance dependence 30.3 SLC6A4 DRD2 BDNF
8 tardive dyskinesia 30.3 HTR2A DRD2 COMT
9 endogenous depression 30.3 SLC6A4 HTR2A HTR1A BDNF
10 panic disorder 30.2 SLC6A4 HTR2A HTR1A COMT
11 neuroleptic malignant syndrome 30.1 HTR1A DRD2
12 schizoaffective disorder 30.1 SLC6A4 HTR2A DTNBP1 DRD2 COMT BDNF
13 depression 30.0 SLC6A4 HTR2C HTR2A HTR1A BDNF
14 cannabis dependence 30.0 NRG1 COMT
15 tobacco addiction 30.0 SLC6A4 HTR2A DRD2 COMT
16 bipolar disorder 29.9 SLC6A4 NRG1 HTR2A HTR1A DTNBP1 DRD2
17 autism spectrum disorder 29.7 SLC6A4 HTR2A BDNF
18 early-onset schizophrenia 29.7 HTR2A DRD2 DRD1 BDNF
19 autism 29.7 SLC6A4 HTR2A HTR1A BDNF
20 mental depression 29.7 SLC6A4 HTR2C HTR2A HTR1A COMT BDNF
21 post-traumatic stress disorder 29.7 SLC6A4 HTR2A DRD2 COMT BDNF
22 agoraphobia 29.7 SLC6A4 HTR1A
23 anxiety 29.5 SLC6A4 HTR2C HTR2A HTR1A COMT BDNF
24 intermittent explosive disorder 29.4 SLC6A4 HTR1A
25 major depressive disorder 29.2 SLC6A4 HTR2C HTR2A HTR1A DRD2 COMT
26 generalized anxiety disorder 29.1 SLC6A4 HTR2A HTR1A DRD2 COMT BDNF
27 personality disorder 29.1 SLC6A4 HTR2C HTR2A HTR1A DRD2 COMT
28 mood disorder 29.0 SLC6A4 PER3 HTR2C HTR2A HTR1A DRD2
29 borderline personality disorder 28.8 SLC6A4 HTR2C HTR2A HTR1A COMT BDNF
30 attention deficit-hyperactivity disorder 28.6 SLC6A4 HTR2C HTR2A HTR1A DRD2 DRD1
31 alcohol dependence 28.5 SLC6A4 HTR2C HTR2A HTR1A DRD2 DRD1
32 migraine with or without aura 1 28.5 SLC6A4 HTR2C HTR2A HTR1A DRD2 COMT
33 obsessive-compulsive disorder 28.2 SLC6A4 HTR2C HTR2A HTR1A DRD2 DRD1
34 schizophrenia 26.4 SLC6A4 NRG1 HTR2C HTR2A HTR1A DTNBP1
35 psychotic disorder 26.2 SLC6A4 NRG1 HTR2C HTR2A HTR1A DTNBP1
36 major affective disorder 8 11.1
37 major affective disorder 9 11.1
38 tic disorder 10.6 HTR2A DRD2
39 polysubstance abuse 10.5 DRD2 COMT
40 alcohol-induced mental disorder 10.5 SLC6A4 DRD2
41 heroin dependence 10.4 DRD2 BDNF
42 atypical depressive disorder 10.4 SLC6A4 HTR2A
43 traumatic brain injury 10.4 DRD2 COMT BDNF
44 brain injury 10.4 DRD2 COMT BDNF
45 postpartum depression 10.4 SLC6A4 COMT BDNF
46 major affective disorder 1 10.4
47 severe combined immunodeficiency 10.4
48 oppositional defiant disorder 10.4 SLC6A4 DRD2 COMT
49 specific developmental disorder 10.4 SLC6A4 COMT BDNF
50 antisocial personality disorder 10.3 SLC6A4 DRD2 COMT

Graphical network of the top 20 diseases related to Bipolar I Disorder:



Diseases related to Bipolar I Disorder

Symptoms & Phenotypes for Bipolar I Disorder

MGI Mouse Phenotypes related to Bipolar I Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 BDNF COMT DAO DRD1 DRD2 DTNBP1
2 homeostasis/metabolism MP:0005376 9.85 BDNF COMT DAO DRD1 DRD2 DTNBP1
3 muscle MP:0005369 9.5 DRD1 DRD2 DTNBP1 EGR3 HTR2A HTR2C
4 nervous system MP:0003631 9.4 BDNF COMT DAO DRD1 DRD2 DTNBP1

Drugs & Therapeutics for Bipolar I Disorder

Drugs for Bipolar I Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxcarbazepine Approved Phase 4 28721-07-5 34312
2
Coal tar Approved Phase 4 8007-45-2
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
5
Ethanol Approved Phase 4 64-17-5 702
6
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
7
Ziprasidone Approved Phase 4 146939-27-7 60854
8
Topiramate Approved Phase 4 97240-79-4 5284627
9
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
10
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
11
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
12
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
13
Infliximab Approved Phase 4 170277-31-3
14
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
15
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
16
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
17
Choline Approved, Nutraceutical Phase 4 62-49-7 305
18 Neurotransmitter Agents Phase 4
19 Dopamine Agents Phase 4
20 Gastrointestinal Agents Phase 4
21 Antiemetics Phase 4
22 Neurotransmitter Uptake Inhibitors Phase 4
23 Peripheral Nervous System Agents Phase 4
24 Diuretics, Potassium Sparing Phase 4
25 Sodium Channel Blockers Phase 4
26 Anti-Infective Agents, Local Phase 4
27 Anti-Infective Agents Phase 4
28 Hormones Phase 4
29 calcium channel blockers Phase 4
30 Calcium, Dietary Phase 4
31 Anti-Obesity Agents Phase 4
32 Appetite Depressants Phase 4
33 Hypoglycemic Agents Phase 4
34 Cyclooxygenase Inhibitors Phase 4
35 Cyclooxygenase 2 Inhibitors Phase 4
36 Anti-Inflammatory Agents, Non-Steroidal Phase 4
37 Anti-Inflammatory Agents Phase 4
38 Antirheumatic Agents Phase 4
39 Lipid Regulating Agents Phase 4
40 Hypolipidemic Agents Phase 4
41 Antimetabolites Phase 4
42 Dopamine Uptake Inhibitors Phase 4
43 Anesthetics, Local Phase 4
44 Nootropic Agents Phase 4
45 Cytidine Diphosphate Choline Phase 4
46 Vasoconstrictor Agents Phase 4
47 Lecithin Phase 4
48 Narcotics Phase 4
49 Narcotic Antagonists Phase 4
50 Dermatologic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 215)
# Name Status NCT ID Phase Drugs
1 ARIQUELI: Potentiation of Quetiapine Treatment in Bipolar 1 Nonresponders Patients With Lithium or Aripiprazole Unknown status NCT01710163 Phase 4 Lithium;Aripiprazole
2 A Randomized Open-label Active-controlled Study to Evaluate the Efficacy and Safety of Utapine Versus Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
3 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
4 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
5 Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder, Manic or Mixed Completed NCT00034580 Phase 4 olanzapine;risperidone
6 A Phase IV, Multi-Center, Open-Label, Safety and Effectiveness Study of Extended-Release Carbamazepine in the Treatment of Mania in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder. Completed NCT00350857 Phase 4 Extended-Release Carbamazepine
7 Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder Completed NCT00190892 Phase 4 olanzapine;carbamazepine
8 A Double-Blind Placebo Controlled Trial of Divalproex and Olanzapine in Bipolar I Disorder, Mixed Episode Completed NCT00402324 Phase 4 olanzapine;placebo;divalproex
9 A Multicenter, Double-blind, Study of the Efficacy and Safety of Aripiprazole in Combination With Lamotrigine in the Long-term Maintenance Treatment of Patients With Bipolar I Disorder With a Recent Manic or Mixed Episode Completed NCT00277212 Phase 4 Lamotrigine + Aripiprazole;Lamotrigine + Placebo
10 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
11 A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia Completed NCT00982020 Phase 4 Olanzapine
12 Efficacy of Aripiprazole in Combination With Lithium or Valproate in the Long-Term Maintenance Treatment of Bipolar I Disorder in Outpatients Partially Nonresponsive to Lithium or Valproate Monotherapy Completed NCT00261443 Phase 4 Lithium or Valproate with placebo (PBO);Lithium or Valproate with Aripiprazole
13 The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
14 Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder Completed NCT00050206 Phase 4 Olanzapine;Placebo
15 A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00139594 Phase 4 licarbazepine
16 A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder Completed NCT00484471 Phase 4 aripiprazole;valproate;placebo
17 Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder Completed NCT00094549 Phase 4 olanzapine;divalproex sodium;placebo
18 An Open Label, 4-Week, Randomised, Multi-Centre, Phase IV Study to Compare the Efficacy and Safety of Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder Completed NCT00672490 Phase 4 Quetiapine Fumarate;Lithium
19 Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression: Role of Inflammation and Kynurenine Pathway Biomarkers Completed NCT01479829 Phase 4 ESC + CBX;ESC + PBO.;ESC+CBX
20 Efficacy and Tolerability of the Combination of LIthium and CArbamazepine Compared to Lithium and VALproic Acid in the Treatment of Young Bipolar Patients Completed NCT00976794 Phase 4 lithium plus carbamazepine;lithium plus valproate
21 Study to Assess the Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Placebo in Patients Ages 10-17 in the Treatment of Major Depressive Episodes Associated With Bipolar I Disorder Completed NCT00844857 Phase 4 Olanzapine Fluoxetine Combination (OFC);Placebo
22 Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents Completed NCT00393978 Phase 4 Quetiapine and placebo;Quetiapine and Topiramate
23 An Open-Label, Flexible-Dose Trial of the Safety and Efficacy of Geodon in Non-Rapid-Cycling Bipolar II Patients With Major Depression Completed NCT00237666 Phase 4 Ziprasidone
24 A Pilot Open Study of the Safety and Effectiveness of Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorders Completed NCT00181844 Phase 4 lamotrigine
25 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
26 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
27 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
28 A Double-Blind, Placebo-Controlled Trial of Seroquel for the Treatment of Dysphoric Hypomania in Bipolar II Patients Completed NCT00186043 Phase 4 Quetiapine/Seroquel;Placebo
29 Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder Completed NCT01588457 Phase 4 Lithium/Lithium Carbonate;Divalproex;Lamotrigine;Quetiapine
30 An Evaluation of the Efficacy of the Tumor Necrosis Factor-alpha Antagonist Infliximab in Treatment Resistant Major Depression: Mechanisms and Mediators Completed NCT00463580 Phase 4 Infliximab;Placebo
31 A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder Recruiting NCT02623504 Phase 4 Carbamazepine;Placebo
32 A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole Recruiting NCT03881449 Phase 4
33 Phase IV Study to Investigate if Valproate Add-on Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients Terminated NCT00139074 Phase 4 Quetiapine fumarate;sodium valproate
34 A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Adjunctive Lithium for the Treatment of Psychotic Mania Followed by an Open Label Long-term Safety Period. Withdrawn NCT01495156 Phase 4 Lithium treatment in combination with a SGA (Second Generation Antipsychotic);Placebo/Adjunctive SGA treatment
35 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Lithium in Bipolar I Disorder Unknown status NCT00422331 Phase 3 Lithium Carbonate Capsule
36 Pediatric Bipolar Collaborative Mood Stabilizer Trial Unknown status NCT00221429 Phase 3 lithium sodium divalproex
37 A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder Completed NCT01059539 Phase 3 Cariprazine
38 A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder. Completed NCT01986114 Phase 3 SM-13496
39 An Open-Label Study to Evaluate the Safety of Depakote ER in the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents Completed NCT00195780 Phase 3 Divalproex Sodium (Depakote ER)
40 A 52-week, Open Label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750 - 2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder. Completed NCT00238485 Phase 3 Licarbazepine
41 An Open-Label Long-Term Study to Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents Completed NCT00195767 Phase 3 divalproex sodium
42 A Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Versus Placebo as Adjunct Therapy With Mood Stabilizers (Lithium or Divalproex) for the Treatment of Alcohol Dependence in Patients With Bipolar I Disorder Completed NCT00114686 Phase 3 Quetiapine fumarate;lithium;divalproex
43 A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750- 2000 mg/Day in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00228059 Phase 3 Licarbazepine
44 A 26-week, Multicenter, Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia (Abbreviated) Completed NCT00227305 Phase 3 quetiapine fumarate
45 A Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of Cariprazine in Patients With Acute Mania Associated With Bipolar I Disorder Completed NCT01058096 Phase 3 Cariprazine;Placebo
46 Placebo- and Haloperidol-Controlled Double-Blind Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder Completed NCT00129220 Phase 3 olanzapine;haloperidol;placebo
47 Study SCA104779, an Evaluation of BW430C (Lamotrigine) Versus Placebo in the Prevention of Mood Episodes in Bipolar I Disorder Patients Completed NCT00550407 Phase 3 lamotrigine;Placebo
48 Safety and Efficacy of Olanzapine (LY170053) in the Long-term Treatment for Patients With Bipolar I Disorder, Depressed Completed NCT00618748 Phase 3 Olanzapine
49 A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Valproate) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients (Abbreviated) Completed NCT00107731 Phase 3 quetiapine fumarate;lithium;divalproex
50 A Randomized, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects With Bipolar I Disorder Completed NCT01358357 Phase 3 Lurasidone;Placebo

Search NIH Clinical Center for Bipolar I Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Aripiprazole
Asenapine
Carbamazepine
Cariprazine
Clonazepam
Lamotrigine
Olanzapine
Quetiapine
Risperidone
Ziprasidone

Genetic Tests for Bipolar I Disorder

Anatomical Context for Bipolar I Disorder

MalaCards organs/tissues related to Bipolar I Disorder:

41
Brain, Cortex, Testes, Amygdala, Prefrontal Cortex, Eye, B Lymphoblasts

Publications for Bipolar I Disorder

Articles related to Bipolar I Disorder:

(show top 50) (show all 2117)
# Title Authors PMID Year
1
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. 38
31255396 2019
2
Cognitive variability in bipolar I disorder: A cluster-analytic approach informed by resting-state data. 38
30914304 2019
3
Asenapine for the treatment of bipolar disorder. 38
31132287 2019
4
Drug induced exanthema and resolution in treatment of Bipolar I Disorder with Lamotrigine and Aripiprazole. 38
31407411 2019
5
Differences between unipolar mania and bipolar-I disorder: Evidence from nine epidemiological studies. 38
30475430 2019
6
Peer support for mood disorder: Characteristics and benefits from attending the Depression and Bipolar Support Alliance mutual-help organization. 38
31150942 2019
7
Lithium prophylaxis in early-onset Bipolar disorder: a descriptive study. 38
31394485 2019
8
Contribution of Rare Copy Number Variants to Bipolar Disorder Risk Is Limited to Schizoaffective Cases. 38
30686506 2019
9
Concurrent, successful management of bipolar I disorder with comorbid alcohol dependence via aripiprazole long-acting injection: A case report. 38
31325244 2019
10
High risk of silent stroke in older bipolar patients with typical-onset age. 38
30734419 2019
11
Auditory steady-state EEG response across the schizo-bipolar spectrum. 38
31080153 2019
12
Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? 38
31355510 2019
13
Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. 38
31344528 2019
14
Drug safety evaluation of aripiprazole in bipolar disorder. 38
31072228 2019
15
Brain function during stages of working memory in schizophrenia and psychotic bipolar disorder. 38
31185485 2019
16
Longitudinal proton spectroscopy study of the prefrontal cortex in youth at risk for bipolar disorder before and after their first mood episode. 38
30864200 2019
17
Low working memory capacity in euthymic bipolar I disorder: No relation to reappraisal on emotion regulation. 38
30986732 2019
18
Psychotic symptoms and suicidal ideation in child and adolescent bipolar I disorder. 38
31025487 2019
19
Association between solar insolation and a history of suicide attempts in bipolar I disorder. 38
30878786 2019
20
Asenapine: Pharmacological Aspects and Role in Psychiatric Disorders. 38
31291219 2019
21
Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. 38
30845817 2019
22
Visual hallucinations associated with multimodal hallucinations, suicide attempts and morbidity of illness in psychotic disorders. 38
30842029 2019
23
Homocysteine, rather than age of onset, is a better predictor for cognitive function in older adults with bipolar disorder. 38
31111977 2019
24
Genome-wide association study identifies 30 loci associated with bipolar disorder. 38
31043756 2019
25
Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department. 38
30548977 2019
26
Network dynamics of positive and negative affect in bipolar disorder. 38
30784724 2019
27
Brain-derived neurotrophic factor (BDNF) and bipolar disorder. 38
30852433 2019
28
Comorbidity of bipolar I disorder and conduct disorder: a familial risk analysis. 38
30758064 2019
29
Shared and dissociable features of apathy and reward system dysfunction in bipolar I disorder and schizophrenia. 38
30994080 2019
30
Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder. 38
30556736 2019
31
Cortical Volume and Thickness Across Bipolar Disorder Subtypes in Adolescents: A Preliminary Study. 38
30359542 2019
32
Double trouble: Weekend sleep changes are associated with increased impulsivity among adolescents with bipolar I disorder. 38
29781205 2019
33
Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. 38
30795492 2019
34
Combined Processing of Facial and Vocal Emotion in Remitted Patients With Bipolar I Disorder. 38
30729905 2019
35
GAD1 gene polymorphisms are associated with bipolar I disorder and with blood homovanillic acid levels but not with plasma GABA levels. 38
30625343 2019
36
Sexual and Religious Obsessions in Relation to Suicidal Ideation in Bipolar Disorder. 38
30729568 2019
37
84 Assessment of Current Clinical Practices in Recognizing and Treating Bipolar Disorder. 38
30859998 2019
38
Response to Lithium in Patients with Bipolar Disorder: What are Psychiatrists' Experiences and Practices Compared to Literature Review? 38
29486511 2019
39
Inflammation associated with volume reduction in the gray matter and hippocampus of older patients with bipolar disorder. 38
30317016 2019
40
Weight gain as a predictor of frontal and temporal lobe volume loss in bipolar disorder: A prospective MRI study. 38
30422375 2019
41
Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy. 38
30489548 2019
42
Substance Use and Psychiatric Disorders Among Mexican Americans and Non-Hispanic Whites by Immigration Status. 38
30817862 2019
43
Transdiagnostic dimensions of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). 38
30600629 2019
44
Validity of the Birchwood insight scale in patients with schizophrenia spectrum- and bipolar disorders. 38
30832191 2019
45
Inflammatory cytokines and cognitive functioning in early-stage bipolar I disorder. 38
30447566 2019
46
Psychoeducation for psychiatric inpatients following remission of a manic episode in bipolar I disorder: A randomized controlled trial. 38
29578271 2019
47
Neurocognition and functional outcome in patients with psychotic, non-psychotic bipolar I disorder, and schizophrenia. A five-year follow-up. 38
30500572 2019
48
98 Dronabinol-Induced Hypomania: A Case Report and Literature Review. 38
30860008 2019
49
Lithium for the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Discontinuation Study. 38
30738555 2019
50
47 Sustained Functional Recovery and Symptom Remission After Maintenance Treatment with Aripiprazole Once-Monthly for Patients with Bipolar I Disorder. 38
30859975 2019

Variations for Bipolar I Disorder

Expression for Bipolar I Disorder

Search GEO for disease gene expression data for Bipolar I Disorder.

Pathways for Bipolar I Disorder

Pathways related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 TUBA8 HTR2C HTR2A DRD2 DRD1 BDNF
2 12.31 HTR1A EGR3 DTNBP1 COMT
3 12.09 HTR1A DRD2 DRD1 BDNF
4
Show member pathways
12.02 HTR2C HTR2A DRD1
6 11.88 SLC6A4 HTR2A HTR1A BDNF
7
Show member pathways
11.74 DRD2 DRD1 BDNF
8 11.68 SLC6A4 HTR2C HTR2A HTR1A
9
Show member pathways
11.6 HTR2C HTR2A HTR1A DRD2 DRD1
10 11.26 DRD2 DRD1 BDNF
11 10.97 TUBA8 HTR2C HTR2A DRD2 DRD1
12
Show member pathways
10.95 SLC6A4 COMT
13 10.87 DRD2 DRD1
14 10.81 HTR2C HTR2A
15 10.7 SLC6A4 HTR2C HTR2A HTR1A

GO Terms for Bipolar I Disorder

Cellular components related to Bipolar I Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 SLC6A4 NRG1 HTR2C HTR2A HTR1A DRD2
2 dendrite GO:0030425 9.8 HTR2C HTR2A HTR1A DRD2 COMT BDNF
3 axon GO:0030424 9.73 NRG1 HTR2A DTNBP1 DRD2 COMT BDNF
4 dendritic spine GO:0043197 9.61 DTNBP1 DRD2 COMT
5 GABA-ergic synapse GO:0098982 9.58 NRG1 DRD2 DRD1
6 non-motile cilium GO:0097730 9.48 DRD2 DRD1
7 integral component of presynaptic membrane GO:0099056 9.46 SLC6A4 HTR2A DRD2 DRD1
8 glutamatergic synapse GO:0098978 9.43 NRG1 HTR2A GRID1 DTNBP1 DRD2 DRD1
9 integral component of postsynaptic membrane GO:0099055 8.92 SLC6A4 HTR2A DRD2 DRD1
10 plasma membrane GO:0005886 10.16 SLC6A4 NRG1 HTR2C HTR2A HTR1A GRID1

Biological processes related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 SLC6A4 NRG1 DTNBP1 DRD1
2 circadian rhythm GO:0007623 9.8 SLC6A4 PER3 EGR3
3 locomotory behavior GO:0007626 9.78 NRG1 HTR2C DRD2 DRD1
4 modulation of chemical synaptic transmission GO:0050804 9.77 GRID1 DRD2 BDNF
5 release of sequestered calcium ion into cytosol GO:0051209 9.73 HTR2C HTR2A DRD2
6 memory GO:0007613 9.73 SLC6A4 HTR2A DRD1 BDNF
7 feeding behavior GO:0007631 9.72 HTR2C DRD2 DRD1
8 behavioral fear response GO:0001662 9.71 HTR2C HTR1A DRD1
9 peripheral nervous system development GO:0007422 9.69 NRG1 EGR3 BDNF
10 regulation of dopamine secretion GO:0014059 9.68 HTR2A DTNBP1
11 adult walking behavior GO:0007628 9.67 DRD2 DRD1
12 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.67 HTR2C DRD1
13 associative learning GO:0008306 9.67 DRD2 DRD1
14 temperature homeostasis GO:0001659 9.67 HTR2A DRD2 DRD1
15 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.67 HTR2C HTR2A HTR1A DRD1
16 activation of phospholipase C activity GO:0007202 9.66 HTR2A BDNF
17 response to light stimulus GO:0009416 9.66 PER3 DRD2
18 synaptic transmission, dopaminergic GO:0001963 9.65 DRD2 DRD1
19 dopamine receptor signaling pathway GO:0007212 9.65 DRD2 DRD1
20 vasoconstriction GO:0042310 9.64 SLC6A4 HTR1A
21 striatum development GO:0021756 9.64 DRD2 DRD1
22 prepulse inhibition GO:0060134 9.63 DRD2 DRD1
23 grooming behavior GO:0007625 9.63 DRD2 DRD1
24 behavioral response to cocaine GO:0048148 9.63 HTR2A DRD2 DRD1
25 regulation of dopamine metabolic process GO:0042053 9.62 HTR1A DRD1
26 synapse assembly GO:0007416 9.62 NRG1 DRD2 DRD1 BDNF
27 peristalsis GO:0030432 9.61 DRD2 DRD1
28 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.61 HTR2A DRD2
29 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.6 DRD2 DRD1
30 cerebral cortex GABAergic interneuron migration GO:0021853 9.58 DRD2 DRD1
31 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.58 DRD2 DRD1
32 dopamine metabolic process GO:0042417 9.58 DRD2 DRD1 COMT
33 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.57 HTR2C HTR2A
34 regulation of synaptic vesicle exocytosis GO:2000300 9.56 HTR2A DTNBP1 DRD2 DRD1
35 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.52 HTR2C HTR2A
36 serotonin receptor signaling pathway GO:0007210 9.33 HTR2C HTR2A HTR1A
37 behavior GO:0007610 9.13 HTR2C HTR2A HTR1A
38 response to drug GO:0042493 9.1 SLC6A4 HTR2C HTR2A DRD2 DRD1 COMT

Molecular functions related to Bipolar I Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.83 HTR2C HTR2A HTR1A DRD2 DRD1
2 drug binding GO:0008144 9.54 HTR2C HTR2A DRD2
3 G-protein alpha-subunit binding GO:0001965 9.46 HTR2A DRD1
4 neurotransmitter receptor activity GO:0030594 9.43 HTR2C HTR2A HTR1A
5 dopamine binding GO:0035240 9.4 DRD2 DRD1
6 G protein-coupled serotonin receptor activity GO:0004993 9.33 HTR2C HTR2A HTR1A
7 dopamine neurotransmitter receptor activity GO:0004952 9.32 DRD2 DRD1
8 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 8.96 HTR2C HTR2A
9 serotonin binding GO:0051378 8.92 SLC6A4 HTR2C HTR2A HTR1A

Sources for Bipolar I Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....